Evidence mapPaperPMID 35880317Full record

ReviewCardiovascular research2023

Obesity and heart failure with preserved ejection fraction: new insights and pathophysiological targets.

Barry A Borlaug, Michael D Jensen, Dalane W Kitzman, Carolyn S P Lam, Masaru Obokata, Oliver J Rider

2 registry-linked trialsAbstract readReview
In one paragraph

Review in Cardiovascular research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 220 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
220citing papers in PubMed, 4 pooled it
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06455878 narecruitingnot on this mapstarted 2024, after this paper: background citation

The Impact of Dietary Management Applet for Weight Reduction in Obese Heart Failure Patients: a Multicenter, Single-blind Randomized Controlled Trial

TypeinterventionalSponsorHeart Health Research CenterRan2024 to 2026Enrolled830ConditionsHeart Failure, Overweight and Obesity, Weight Loss, Heart Failure With Reduced Ejection FractionArmsFull usage of diet management app group and with the full usage of an intelligent weight scale, Limited usage of diet management app group and with the limited usage of an intelligent weight scale
NCT07539766 recruitingnot on this mapstarted 2025, after this paper: background citation

OBESE-HFpEF: Prevalence and Mediators of Heart Failure (Preserved Ejection Fraction) in the Dutch Obesity Clinic South - Towards Preventing Obesity Related HFpEF''

Typeobservational_patient_registrySponsorZuyderland Medisch CentrumRan2025 to 2029Enrolled250ConditionsHeart Failure and Preserved Ejection Fraction, Obesity (Disorder), Heart Failure
3 · Its place in the literature

Who cites it

220 citing papers in PubMed, 4 syntheses or guidelines pooled it.

  1. Pooled it
  2. CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne · 2025
    Guideline
  3. Pharmacotherapy for obesity management in adults: 2025 clinical practice guideline update.CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne · 2025
    Guideline
  4. Pooled it
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. Trial
  16. Trial
  17. Trial
  18. Trial
  19. Review
  20. Article

160 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Barry A BorlaugDepartment of Cardiovascular Diseases, Mayo Clinic Rochester, 200 First Street SW, Rochester, MN 55905, USA.ORCID 0000-0001-9375-0596
Michael D JensenEndocrine Research Unit, Mayo Clinic, Rochester, MN, USA.
Dalane W KitzmanDepartment of Internal Medicine, Section on Cardiology, Wake Forest School of Medicine, Winston-Salem, NC, USA.
Carolyn S P LamDuke-National University of Singapore, Singapore, Singapore.
Masaru ObokataDepartment of Cardiovascular Medicine, Gunma University Graduate School of Medicine, Maebashi, Gunma, Japan.ORCID 0000-0002-5473-0688
Oliver J RiderDivision of Cardiovascular Medicine, Radcliffe Department of Medicine, Oxford Centre for Clinical Magnetic Resonance Research, University of Oxford, Oxford, UK.

Funding

REGIONAL FATTY ACID METABOLISM IN HUMANSR01DK045343 · MAYO CLINIC ROCHESTER · 1992 to 2025
$3.2M
Wake Forest Atrium HeartShare Clinical CenterU01HL160272 · WAKE FOREST UNIVERSITY HEALTH SCIENCES · 2025 to 2025
$529k
British Heart Foundation FS/16/70/32157British Heart Foundation FS/SCRF/22/32014NHLBI NIH HHS U01 HL160272NIDDK NIH HHS R01 DK045343NIH HHS R01 HL128526
6 · The paper itself

Abstract

Obesity and heart failure with preserved ejection fraction (HFpEF) represent two intermingling epidemics driving perhaps the greatest unmet health problem in cardiovascular medicine in the 21st century. Many patients with HFpEF are either overweight or obese, and recent data have shown that increased body fat and its attendant metabolic sequelae have widespread, protean effects systemically and on the cardiovascular system leading to symptomatic HFpEF. The paucity of effective therapies in HFpEF underscores the importance of understanding the distinct pathophysiological mechanisms of obese HFpEF to develop novel therapies. In this review, we summarize the current understanding of the cardiovascular and non-cardiovascular features of the obese phenotype of HFpEF, how increased adiposity might pathophysiologically contribute to the phenotype, and how these processes might be targeted therapeutically.

Indexed as

Heart FailureAdiposityHeartHumansObesityStroke VolumeAdiposityHeart failureHFpEFInflammationObesityphenotype

Identifiers

PMID35880317
PMCPMC10202444

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.